Jade Biosciences Announces $135 Million Private Placement
Jade Biosciences, Inc. (JBIO)
Company Research
Source: GlobeNewswire
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace, Aberdeen Investments, Great Point Partners, LLC, Venrock Healthcare Capital Partners, Samsara BioCapital, Avidity Partners, and several other leading healthcare investors. Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of (i) 13,368,164 shares of its com
Show less
Read more
Impact Snapshot
Event Time:
JBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JBIO alerts
High impacting Jade Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JBIO
News
- What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Jade Biosciences (NASDAQ:JBIO) had its price target raised by analysts at Guggenheim from $14.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (NASDAQ:JBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=JBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 [Yahoo! Finance]Yahoo! Finance
- Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025GlobeNewswire
JBIO
Earnings
- 11/13/25 - Beat
JBIO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form S-1
- 11/14/25 - Form SCHEDULE
- JBIO's page on the SEC website